Funded Project Details - FY2021
|Title:|| Building a New Therapeutic Paradigm for Hepatocellular Cancer by Dissecting the Interaction between Radiofrequency Ablation, Chemotherapy, and Immunotherapy|
Eric T Kimchi
|Congressional District Code:
||Biomedical Laboratory R&D
|| January 2019 -
|FY 2021 Funding Amount:
|Total Award Amount
View full abstract and other project information on NIH RePORTER
Go To NIH RePORTER
Hepatocellular cancer (HCC) remains one of the deadliest cancers with limited clinical options. Due of life style choices, living conditions, and/or environmental elements, risk factors for the development of HCC cause the increased incidence in military service members, veterans, and their families with 10-fold higher than the general population. Radiofrequency ablation (RFA) has emerged as a first line treatment option for patients with HCC. When combined with modern imaging, RFA can be perfor...
Questions about the R&D website? Email the Web Team
Any health information on this website is strictly for informational purposes and is not intended as medical advice. It should not be used to diagnose or treat any condition.